The bystander effect seen with T-DXd, deemed valuable in overcoming heterogenous HER2 expression, also has the potential to overhaul the treatment paradigm of advanced gastric cancers by introducing the concept of HER2-low disease. The gene discussed is ERBB2; the disease is gastric cancer.